We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are going to take a look at where ...

Axsome Therapeutics (NASDAQ:AXSM) has received FDA approval for its drug Symbravo for the acute treatment of migraine with or ...

Else Nutrition Holdings Inc (ELSE) reported a robust start to 2022 with significant revenue growth and improved profitability. The company, known for its plant-based, dairy-free nutrition products, ...

According to a report by the Australian Bureau of Statistics (ABS) published on December 4, 2024, the Australian economy grew ...

Chimerix Inc (NASDAQ: NASDAQ:CMRX) stock has reached a new 52-week high, touching $4.22 in recent trading, giving the company a market capitalization of $375 million. According to InvestingPro data, ...

Clinical-stage biopharmaceutical company Tonix Pharmaceuticals (NASDAQ: TNXP) is gaining significant attention from investors and market participants. The company develops therapies for conditions ...

Verona Pharma (NASDAQ:VRNA)'s stock has reached an unprecedented peak, setting an all-time high at $56.49. This milestone underscores a remarkable period of growth for the $4.49 billion ...

Vir Biotechnology, Inc., a $1.5 billion market cap biotech company, announced a change in its executive team with the upcoming departure of Ann (Aine) M. Hanly, Ph.D., and the appointment of Maninder ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...

Bioxyne lifts revenue 77% QoQ; Radiopharm listed on the Nasdaq in the December quarter; Tryptomine hits key milestones; Quarterly season is nearing its end, triggering a rush from ...

Several ASX-listed companies are undertaking phase III clinical trials, the critical final stage before potential regulatory ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a commercial-stage biopharmaceutical company with a "GOOD" InvestingPro Financial ...